berberine has been researched along with Obesity in 67 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study provides a critical overview of experimental studies in vitro, in humans, and in animals that evaluated the efficacy of Berberine and its effect on management of obesity and the related metabolic consequences." | 9.05 | The effect of Berberine on weight loss in order to prevent obesity: A systematic review. ( Al-Thawadi, S; Alalwan, TA; Gasparri, C; Ilyas, Z; Infantino, V; Perna, S; Peroni, G; Petrangolini, G; Riva, A; Rondanelli, M, 2020) |
| " All clinical trials exploring the effects of berberine supplementation on indices of obesity were included." | 9.05 | The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. ( Clark, CCT; Dorosti, M; Găman, MA; Kord-Varkaneh, H; Mousavi, SM; Niu, L; Rahmani, J; Taghizade-Bilondi, H; Talaei, S; Xiong, P; Zarezadeh, M; Zhang, J, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 8.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "To investigate whether astragalus polysaccharides (APS) combined with berberine (BBR) can reduce high-fat diet (HFD)-induced obesity in mice." | 8.31 | Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. ( Feng, WW; Gao, H; Liu, J; Tang, YP; Wang, WX; Yan, D; Yue, SJ; Zhang, L, 2023) |
| "Berberine (BBR) exerts specific therapeutic effects on various diseases such as diabetes, obesity, and other inflammation-associated diseases." | 8.12 | A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ. ( Liu, X; Lu, Y; Qiu, S; Wang, M; Xu, R; Yan, M; Zhang, L; Zhang, P; Zhu, J, 2022) |
| "Although oral berberine, a natural compound extracted from the Chinese herbal medicine curcumin, has low bioavailability, it is still effective in suppressing obesity; however, the underlying mechanism is unclear." | 8.12 | Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut. ( Chen, L; Hou, M; Ji, M; Ma, X; Ni, Y; Sun, S; Xiong, R; Xu, Z; Yang, Y, 2022) |
| "Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota." | 8.02 | Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. ( Jiang, Y; Kong, Y; Liu, H; Ren, H; Shan, C; Wang, J; Wang, S; Wang, Y; Yang, J; Yang, Y; Zheng, M, 2021) |
| "Berberine (BBR) has been widely used to treat non-alcoholic fatty liver disease (NAFLD)." | 8.02 | Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. ( Chen, HB; Chen, JN; Dou, YX; Huang, XQ; Huang, ZW; Li, QP; Li, YC; Liu, YH; Su, ZR; Xie, JH; Yang, XB; Zeng, HF, 2021) |
| " To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated." | 7.96 | Berberine for Appetite Suppressant and Prevention of Obesity. ( Jung, E; Park, HJ; Shim, I, 2020) |
| " At present, researches have presented obesity is a high-risk factor for colitis, and berberine shows positive therapeutic effect on colitis." | 7.96 | Regulation of MFN2 by berberine alleviates obesity exacerbated colitis. ( Chen, Y; Liu, F; Wen, S; Zheng, Y, 2020) |
| "Berberine has been established as a potential drug for inflammation and metabolic disorder." | 7.96 | Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu. ( Fan, DH; Han, YB; Li, WZ; Liu, L; Tian, M; Wang, XX; Wu, F, 2020) |
| "This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD)." | 7.91 | Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. ( Chen, RS; Chen, YN; Deng, YJ; Han, L; Jin, L; Liang, S; Liang, YJ; Liang, ZE; Tang, KR; Yang, QH; Zhang, YP, 2019) |
| "Berberine, a natural compound extracted from several Chinese herbs including Coptis chinensis, has been shown to have anti-obesity effects and prevents insulin resistance in high-fat diet (HFD)-fed obese rats by modulating the gut microbiota; however, the molecular mechanisms underlying these activities remain unknown." | 7.88 | Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. ( Hou, L; Li, S; Liu, D; Liu, Y; Tian, H; Zhang, Y; Zhao, T, 2018) |
| " In the present study reverse transcription-polymerase chain reaction, immunofluorescence, pyrosequencing, ELISA and Oil Red O staining were performed to assess whether berberine can protect against diet-induced obesity, through modulating the gut microbiota and consequently improving metabolic endotoxemia and gastrointestinal hormone levels." | 7.85 | Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. ( Liu, XZ; Pan, W; Xu, JH; Zou, DJ, 2017) |
| "Increasing evidence demonstrates that berberine (BBR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD)." | 7.83 | Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. ( Botchlett, R; Cai, Y; Chen, L; Guo, T; Guo, X; Huo, Y; Li, H; Li, Q; Li, X; Liu, M; Pei, Y; Woo, SL; Wu, C; Xiao, X; Xu, H; Zeng, T; Zheng, J, 2016) |
| "Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway." | 7.81 | [Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]. ( Bai, XH; Chen, J; Mu, DZ; Yao, YJ; Zhang, DS, 2015) |
| " Rhizoma coptidis (RC) and its main active compound, berberine, have either antimicrobial or anti-obesity activities." | 7.77 | Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. ( Cui, K; Gu, D; Li, J; Xie, W; Zhang, Y, 2011) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 7.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "Obesity is defined as a dampness-heat syndrome in traditional Chinese medicine." | 5.91 | Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPARδ. ( Shaw, PC; Shou, JW, 2023) |
| "Berberine (BBR), which is a compound derived from the Chinese medicinal plant Coptis chinensis, promotes weight loss, but the molecular mechanisms are not well understood." | 5.91 | Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. ( Gong, S; Hu, F; Leng, Q; Li, C; Li, L; Li, X; Xu, Y; Yang, Y; Zhang, H, 2023) |
| "Obesity is closely related to diabetes." | 5.72 | Jatrorrhizine from Rhizoma Coptidis exerts an anti-obesity effect in db/db mice. ( An, L; Deng, J; He, H; Li, X; Yang, M; Ye, X, 2022) |
| "Berberine (BBR) has many pharmacological properties and is used as an insulin sensitizer." | 5.62 | Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. ( Li, XL; Shen, HR; Xu, X, 2021) |
| "Berberine (BBR) has been shown to relieve several metabolic disorders, including obesity and type 2 diabetes." | 5.48 | Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice. ( Hua, Y; Song, Y; Wang, L; Ye, X, 2018) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 5.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Berberine has been reported to have antidiabetic properties." | 5.36 | Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. ( Huang, L; Li, G; Liu, X; Liu, Y; Ma, C; Qin, C; Zhu, H, 2010) |
| " Berberine is a famous natural compound from medicinal herbs and shows many bioactivities, such as antioxidant, anti-inflammatory, antidiabetic, anti-obesity, and antimicrobial activities." | 5.22 | Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review. ( Gan, RY; Huang, SY; Li, HB; Saimaiti, A; Shang, A; Wu, SX; Xiong, RG; Yang, ZJ; Zhang, YJ; Zhao, CN; Zhou, DD, 2022) |
| " All clinical trials exploring the effects of berberine supplementation on indices of obesity were included." | 5.05 | The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. ( Clark, CCT; Dorosti, M; Găman, MA; Kord-Varkaneh, H; Mousavi, SM; Niu, L; Rahmani, J; Taghizade-Bilondi, H; Talaei, S; Xiong, P; Zarezadeh, M; Zhang, J, 2020) |
| "This study provides a critical overview of experimental studies in vitro, in humans, and in animals that evaluated the efficacy of Berberine and its effect on management of obesity and the related metabolic consequences." | 5.05 | The effect of Berberine on weight loss in order to prevent obesity: A systematic review. ( Al-Thawadi, S; Alalwan, TA; Gasparri, C; Ilyas, Z; Infantino, V; Perna, S; Peroni, G; Petrangolini, G; Riva, A; Rondanelli, M, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 4.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "To investigate whether astragalus polysaccharides (APS) combined with berberine (BBR) can reduce high-fat diet (HFD)-induced obesity in mice." | 4.31 | Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. ( Feng, WW; Gao, H; Liu, J; Tang, YP; Wang, WX; Yan, D; Yue, SJ; Zhang, L, 2023) |
| "Although oral berberine, a natural compound extracted from the Chinese herbal medicine curcumin, has low bioavailability, it is still effective in suppressing obesity; however, the underlying mechanism is unclear." | 4.12 | Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut. ( Chen, L; Hou, M; Ji, M; Ma, X; Ni, Y; Sun, S; Xiong, R; Xu, Z; Yang, Y, 2022) |
| "Berberine (BBR) has been found to have antiobesity effects, and obesity can lead to adipose tissue degeneration." | 4.12 | Berberine ameliorates mesenteric vascular dysfunction by modulating perivascular adipose tissue in diet-induced obese in rats. ( Duan, X; Geng, X; Hou, C; Li, K; Wang, M; Wang, Y; Zhao, D; Zhao, L; Zhou, H, 2022) |
| "Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota." | 4.02 | Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. ( Jiang, Y; Kong, Y; Liu, H; Ren, H; Shan, C; Wang, J; Wang, S; Wang, Y; Yang, J; Yang, Y; Zheng, M, 2021) |
| "Berberine (BBR) has been widely used to treat non-alcoholic fatty liver disease (NAFLD)." | 4.02 | Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. ( Chen, HB; Chen, JN; Dou, YX; Huang, XQ; Huang, ZW; Li, QP; Li, YC; Liu, YH; Su, ZR; Xie, JH; Yang, XB; Zeng, HF, 2021) |
| " To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated." | 3.96 | Berberine for Appetite Suppressant and Prevention of Obesity. ( Jung, E; Park, HJ; Shim, I, 2020) |
| " Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials." | 3.96 | Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020) |
| "Berberine has been established as a potential drug for inflammation and metabolic disorder." | 3.96 | Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu. ( Fan, DH; Han, YB; Li, WZ; Liu, L; Tian, M; Wang, XX; Wu, F, 2020) |
| " At present, researches have presented obesity is a high-risk factor for colitis, and berberine shows positive therapeutic effect on colitis." | 3.96 | Regulation of MFN2 by berberine alleviates obesity exacerbated colitis. ( Chen, Y; Liu, F; Wen, S; Zheng, Y, 2020) |
| "This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD)." | 3.91 | Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. ( Chen, RS; Chen, YN; Deng, YJ; Han, L; Jin, L; Liang, S; Liang, YJ; Liang, ZE; Tang, KR; Yang, QH; Zhang, YP, 2019) |
| "Berberine, a natural compound extracted from several Chinese herbs including Coptis chinensis, has been shown to have anti-obesity effects and prevents insulin resistance in high-fat diet (HFD)-fed obese rats by modulating the gut microbiota; however, the molecular mechanisms underlying these activities remain unknown." | 3.88 | Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. ( Hou, L; Li, S; Liu, D; Liu, Y; Tian, H; Zhang, Y; Zhao, T, 2018) |
| " In the present study reverse transcription-polymerase chain reaction, immunofluorescence, pyrosequencing, ELISA and Oil Red O staining were performed to assess whether berberine can protect against diet-induced obesity, through modulating the gut microbiota and consequently improving metabolic endotoxemia and gastrointestinal hormone levels." | 3.85 | Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. ( Liu, XZ; Pan, W; Xu, JH; Zou, DJ, 2017) |
| "Increasing evidence demonstrates that berberine (BBR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD)." | 3.83 | Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. ( Botchlett, R; Cai, Y; Chen, L; Guo, T; Guo, X; Huo, Y; Li, H; Li, Q; Li, X; Liu, M; Pei, Y; Woo, SL; Wu, C; Xiao, X; Xu, H; Zeng, T; Zheng, J, 2016) |
| " Berberine, a benzylisoquinoline plant alkaloid, has been extensively investigated for its anti-obesity effects and as a potential cholesterol and triglyceride-lowering drug." | 3.83 | 13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells. ( Chow, YL; Sato, F; Sogame, M, 2016) |
| "Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway." | 3.81 | [Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]. ( Bai, XH; Chen, J; Mu, DZ; Yao, YJ; Zhang, DS, 2015) |
| "Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance." | 3.78 | Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. ( Duarte, FV; Gomes, AP; Hubbard, BP; Jones, JG; Nunes, P; Palmeira, CM; Rolo, AP; Sinclair, DA; Teodoro, JS; Varela, AT, 2012) |
| " Rhizoma coptidis (RC) and its main active compound, berberine, have either antimicrobial or anti-obesity activities." | 3.77 | Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. ( Cui, K; Gu, D; Li, J; Xie, W; Zhang, Y, 2011) |
| " Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR)." | 3.76 | Berberine inhibits PTP1B activity and mimics insulin action. ( Chen, C; Huang, C; Zhang, Y, 2010) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 3.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world." | 2.72 | Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. ( Li, L; Xie, J; Zhao, L, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients." | 2.58 | Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. ( Bellentani, S; Cicero, AFG; Colletti, A, 2018) |
| "Berberine has significant antimicrobial activity against several microbes through inhibiting the assembly function of FtsZ and halting the bacteria cell division." | 2.47 | Modulating gut microbiota as an anti-diabetic mechanism of berberine. ( Han, J; Huang, W; Lin, H, 2011) |
| " However, as the two agents have very different chemical structure and bioavailability in oral route, the goal of this study is to learn their characteristics in treating metabolic disorders." | 1.91 | Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. ( Gao, TL; Guo, HH; Han, YX; Jiang, JD; Luo, ZG; Shen, HR; Wang, LL; Zhang, HJ; Zhang, JL, 2023) |
| "Berberine (BBR), which is a compound derived from the Chinese medicinal plant Coptis chinensis, promotes weight loss, but the molecular mechanisms are not well understood." | 1.91 | Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. ( Gong, S; Hu, F; Leng, Q; Li, C; Li, L; Li, X; Xu, Y; Yang, Y; Zhang, H, 2023) |
| "Berberine chloride is a dual topoisomerase I and II inhibitor, that exhibited potent antitumor activities against several malignancies." | 1.91 | Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production. ( Abdalla, M; Ferdous, MR; Song, Y; Xiaoling, L; Yang, M, 2023) |
| "Obesity is an established risk factor for metabolic disease." | 1.72 | Functional Complementation of Anti-Adipogenic Phytonutrients for Obesity Prevention and Management. ( Le, TT; Urasaki, Y, 2022) |
| "Obesity is closely related to diabetes." | 1.72 | Jatrorrhizine from Rhizoma Coptidis exerts an anti-obesity effect in db/db mice. ( An, L; Deng, J; He, H; Li, X; Yang, M; Ye, X, 2022) |
| "Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese herbs and exhibits glucose lowering properties." | 1.62 | Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus. ( Chen, L; Cole, LK; Dolinsky, VW; Hatch, GM; Sparagna, GC; Vandel, M; Xiang, B; Zhang, M, 2021) |
| "Berberine (BBR) has many pharmacological properties and is used as an insulin sensitizer." | 1.62 | Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. ( Li, XL; Shen, HR; Xu, X, 2021) |
| "Berberine (BBR) has been shown to relieve several metabolic disorders, including obesity and type 2 diabetes." | 1.48 | Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice. ( Hua, Y; Song, Y; Wang, L; Ye, X, 2018) |
| " However, the implication of these mechanisms is unclear because of the low bioavailability of BBR." | 1.46 | Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. ( Aa, J; Aa, N; Cao, B; Chen, Q; Fei, F; Feng, D; Feng, S; Ge, C; Guo, GL; Guo, J; He, J; Huang, J; Kong, B; Pan, Y; Schumacher, JD; Shen, J; Sun, R; Wang, G; Wang, P; Yang, CS; Yang, N; Yu, X, 2017) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 1.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Berberine (BBR) is a compound derived from the Chinese medicinal plant Coptis chinensis." | 1.40 | Berberine activates thermogenesis in white and brown adipose tissue. ( Jin, L; Li, B; Ma, Q; Meng, X; Ning, G; Wang, J; Wang, W; Yang, J; Yao, S; Zhang, H; Zhang, Y; Zhang, Z, 2014) |
| "Obesity is a major cause of metabolic syndrome and is due to an increase in the number and hypertrophy of adipocytes." | 1.38 | Inhibition of preadipocyte differentiation and lipid accumulation by Orengedokuto treatment of 3T3-L1 cultures. ( Ikarashi, N; Ito, K; Ochiai, W; Sugiyama, K; Suzuki, K; Tajima, M; Toda, T, 2012) |
| "Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine." | 1.38 | Possible therapeutic potential of berberine in diabetic osteopathy. ( Bhutada, PS; Kaulaskar, SV; Rahigude, AB, 2012) |
| " In diet-induced obese (DIO) mice, Di-Me counteracted the increased adiposity, tissue triglyceride accumulation and insulin resistance, and improved glucose tolerance at a dosage of 15mg/kg." | 1.36 | 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. ( Chen, AF; Cheng, Z; Gu, M; Hu, LH; Li, J; Li, JY; Li, YY; Sheng, L; Wu, F; Zhang, HK; Zhang, LN, 2010) |
| "Berberine has been reported to have antidiabetic properties." | 1.36 | Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. ( Huang, L; Li, G; Liu, X; Liu, Y; Ma, C; Qin, C; Zhu, H, 2010) |
| " Mice in BL and BH were administered berberine by gavage at the dosage of 50 mg x kg(-1) and 150 mg x kg(-1), respectively." | 1.36 | [Effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet]. ( Liu, J; Shang, W; Yu, X; Zhao, J, 2010) |
| "Berberine has hypoglycemic and hypolipidemic effects on diabetic rats." | 1.36 | Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. ( Zhou, J; Zhou, S, 2010) |
| "Berberine treatment resulted in increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 adipocytes and L6 myotubes, increased GLUT4 translocation in L6 cells in a phosphatidylinositol 3' kinase-independent manner, and reduced lipid accumulation in 3T3-L1 adipocytes." | 1.33 | Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. ( Cho, HJ; Gosby, A; Hohnen-Behrens, C; James, DE; Kim, CT; Kim, JB; Kim, KH; Kim, WS; Kraegen, EW; Lee, CH; Lee, YS; Oh, WK; Shen, Y; Ye, JM; Yoon, MJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (4.48) | 29.6817 |
| 2010's | 37 (55.22) | 24.3611 |
| 2020's | 27 (40.30) | 2.80 |
| Authors | Studies |
|---|---|
| Yue, SJ | 2 |
| Wang, WX | 1 |
| Zhang, L | 3 |
| Liu, J | 3 |
| Feng, WW | 1 |
| Gao, H | 1 |
| Tang, YP | 1 |
| Yan, D | 2 |
| Ferdous, MR | 1 |
| Abdalla, M | 1 |
| Yang, M | 2 |
| Xiaoling, L | 1 |
| Song, Y | 2 |
| He, H | 1 |
| Deng, J | 1 |
| An, L | 1 |
| Ye, X | 2 |
| Li, X | 4 |
| Wang, M | 2 |
| Geng, X | 1 |
| Li, K | 1 |
| Wang, Y | 3 |
| Duan, X | 1 |
| Hou, C | 1 |
| Zhao, L | 4 |
| Zhou, H | 1 |
| Zhao, D | 1 |
| Xiong, RG | 1 |
| Huang, SY | 1 |
| Wu, SX | 1 |
| Zhou, DD | 1 |
| Yang, ZJ | 1 |
| Saimaiti, A | 1 |
| Zhao, CN | 1 |
| Shang, A | 1 |
| Zhang, YJ | 1 |
| Gan, RY | 1 |
| Li, HB | 1 |
| Xu, R | 1 |
| Liu, X | 2 |
| Qiu, S | 1 |
| Lu, Y | 2 |
| Zhang, P | 1 |
| Yan, M | 1 |
| Zhu, J | 1 |
| Urasaki, Y | 2 |
| Le, TT | 2 |
| Sun, S | 1 |
| Yang, Y | 3 |
| Xiong, R | 1 |
| Ni, Y | 1 |
| Ma, X | 1 |
| Hou, M | 1 |
| Chen, L | 4 |
| Xu, Z | 1 |
| Ji, M | 1 |
| Li, C | 1 |
| Leng, Q | 1 |
| Li, L | 2 |
| Hu, F | 1 |
| Xu, Y | 2 |
| Gong, S | 1 |
| Zhang, H | 2 |
| Guo, HH | 1 |
| Shen, HR | 2 |
| Wang, LL | 1 |
| Luo, ZG | 1 |
| Zhang, JL | 1 |
| Zhang, HJ | 1 |
| Gao, TL | 1 |
| Han, YX | 1 |
| Jiang, JD | 2 |
| Shou, JW | 1 |
| Shaw, PC | 1 |
| Wang, C | 1 |
| Ma, SR | 1 |
| Zuo, ZY | 1 |
| Wu, YB | 1 |
| Kong, WJ | 1 |
| Wang, AP | 1 |
| Zhang, W | 1 |
| Xu, JH | 2 |
| Yu, T | 1 |
| Chen, QK | 1 |
| Payab, M | 1 |
| Hasani-Ranjbar, S | 1 |
| Baeeri, M | 1 |
| Rahimifard, M | 1 |
| Arjmand, B | 1 |
| Haghi-Aminjan, H | 1 |
| Abdollahi, M | 1 |
| Larijani, B | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Singh, DP | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Ilyas, Z | 1 |
| Perna, S | 1 |
| Al-Thawadi, S | 1 |
| Alalwan, TA | 1 |
| Riva, A | 1 |
| Petrangolini, G | 1 |
| Gasparri, C | 1 |
| Infantino, V | 1 |
| Peroni, G | 1 |
| Rondanelli, M | 1 |
| Xiong, P | 1 |
| Niu, L | 1 |
| Talaei, S | 1 |
| Kord-Varkaneh, H | 1 |
| Clark, CCT | 1 |
| Găman, MA | 1 |
| Rahmani, J | 1 |
| Dorosti, M | 1 |
| Mousavi, SM | 1 |
| Zarezadeh, M | 1 |
| Taghizade-Bilondi, H | 1 |
| Zhang, J | 1 |
| Qian, S | 1 |
| Ma, L | 1 |
| Peng, S | 1 |
| Wu, K | 1 |
| Shen, S | 1 |
| Zhang, X | 7 |
| Sun, Y | 2 |
| Ye, J | 3 |
| Han, YB | 1 |
| Tian, M | 1 |
| Wang, XX | 1 |
| Fan, DH | 1 |
| Li, WZ | 1 |
| Wu, F | 2 |
| Liu, L | 1 |
| Asbaghi, O | 1 |
| Ghanbari, N | 1 |
| Shekari, M | 1 |
| Reiner, Ž | 1 |
| Amirani, E | 1 |
| Hallajzadeh, J | 1 |
| Mirsafaei, L | 1 |
| Asemi, Z | 1 |
| Chen, Y | 1 |
| Zheng, Y | 1 |
| Wen, S | 1 |
| Liu, F | 1 |
| Xu, X | 2 |
| Li, XL | 1 |
| Park, HJ | 1 |
| Jung, E | 1 |
| Shim, I | 1 |
| Cole, LK | 1 |
| Zhang, M | 3 |
| Sparagna, GC | 1 |
| Vandel, M | 1 |
| Xiang, B | 1 |
| Dolinsky, VW | 1 |
| Hatch, GM | 1 |
| Xie, J | 1 |
| Li, QP | 1 |
| Dou, YX | 1 |
| Huang, ZW | 1 |
| Chen, HB | 1 |
| Li, YC | 1 |
| Chen, JN | 1 |
| Liu, YH | 1 |
| Huang, XQ | 1 |
| Zeng, HF | 1 |
| Yang, XB | 1 |
| Su, ZR | 1 |
| Xie, JH | 1 |
| Liu, H | 1 |
| Zheng, M | 1 |
| Ren, H | 1 |
| Kong, Y | 1 |
| Wang, S | 1 |
| Wang, J | 2 |
| Jiang, Y | 1 |
| Yang, J | 2 |
| Shan, C | 1 |
| Li, D | 1 |
| Yang, C | 1 |
| Zhu, JZ | 1 |
| Lopez, E | 1 |
| Zhang, T | 1 |
| Tong, Q | 1 |
| Peng, C | 2 |
| Lin, LG | 1 |
| Liu, XZ | 1 |
| Pan, W | 1 |
| Zou, DJ | 1 |
| Liu, D | 2 |
| Zhang, Y | 6 |
| Liu, Y | 2 |
| Hou, L | 1 |
| Li, S | 1 |
| Tian, H | 1 |
| Zhao, T | 1 |
| Wang, L | 1 |
| Hua, Y | 1 |
| Cazzaniga, M | 1 |
| Bonanni, B | 1 |
| Cicero, AFG | 1 |
| Colletti, A | 1 |
| Bellentani, S | 1 |
| Jin, C | 1 |
| Jia, W | 1 |
| Le, J | 1 |
| Wang, AT | 1 |
| Meng, XT | 1 |
| Yang, ZR | 1 |
| Guan, HS | 1 |
| Wang, CY | 1 |
| Lin, J | 1 |
| Cai, Q | 1 |
| Liang, B | 1 |
| Wu, L | 2 |
| Zhuang, Y | 1 |
| He, Y | 1 |
| Lin, W | 1 |
| Zhu, XP | 1 |
| Bai, JY | 1 |
| Xia, P | 1 |
| Li, Y | 1 |
| Li, XY | 1 |
| Gao, X | 2 |
| Zhang, YP | 1 |
| Deng, YJ | 1 |
| Tang, KR | 1 |
| Chen, RS | 1 |
| Liang, S | 1 |
| Liang, YJ | 1 |
| Han, L | 1 |
| Jin, L | 2 |
| Liang, ZE | 1 |
| Chen, YN | 1 |
| Yang, QH | 1 |
| Jia, D | 1 |
| Li, ZW | 1 |
| Zhou, X | 1 |
| Gao, Y | 1 |
| Feng, Y | 1 |
| Ma, M | 1 |
| Wu, Z | 1 |
| Li, W | 1 |
| Hirai, T | 1 |
| Mitani, Y | 1 |
| Kurumisawa, K | 1 |
| Nomura, K | 1 |
| Wang, W | 2 |
| Nakashima, KI | 1 |
| Inoue, M | 1 |
| Xia, M | 1 |
| Duan, Y | 1 |
| Jiang, H | 1 |
| Hu, X | 1 |
| Yan, H | 1 |
| Gu, Y | 1 |
| Shi, H | 1 |
| Li, J | 4 |
| Zhang, Z | 2 |
| Li, B | 1 |
| Meng, X | 1 |
| Yao, S | 1 |
| Ma, Q | 1 |
| Ning, G | 2 |
| Zou, ZY | 1 |
| Hu, YR | 1 |
| Ma, H | 1 |
| Wang, YZ | 1 |
| He, K | 1 |
| Xia, S | 1 |
| Wu, H | 1 |
| Xue, DF | 1 |
| Li, XG | 1 |
| Ye, XL | 1 |
| Zhao, Y | 2 |
| Xu, J | 2 |
| Xue, Z | 1 |
| Pang, X | 2 |
| Zhang, DS | 1 |
| Bai, XH | 1 |
| Yao, YJ | 1 |
| Mu, DZ | 1 |
| Chen, J | 1 |
| Guo, T | 1 |
| Woo, SL | 1 |
| Guo, X | 1 |
| Li, H | 1 |
| Zheng, J | 1 |
| Botchlett, R | 1 |
| Liu, M | 1 |
| Pei, Y | 1 |
| Xu, H | 1 |
| Cai, Y | 1 |
| Zeng, T | 1 |
| Li, Q | 1 |
| Xiao, X | 1 |
| Huo, Y | 1 |
| Wu, C | 1 |
| Yang, W | 1 |
| She, L | 1 |
| Yu, K | 1 |
| Yan, S | 1 |
| Tian, X | 1 |
| Ma, S | 1 |
| Chow, YL | 1 |
| Sogame, M | 1 |
| Sato, F | 1 |
| Sun, R | 1 |
| Yang, N | 1 |
| Kong, B | 1 |
| Cao, B | 1 |
| Feng, D | 1 |
| Yu, X | 2 |
| Ge, C | 1 |
| Huang, J | 1 |
| Shen, J | 1 |
| Wang, P | 1 |
| Feng, S | 1 |
| Fei, F | 1 |
| Guo, J | 1 |
| He, J | 1 |
| Aa, N | 1 |
| Chen, Q | 1 |
| Pan, Y | 1 |
| Schumacher, JD | 1 |
| Yang, CS | 1 |
| Guo, GL | 1 |
| Aa, J | 1 |
| Wang, G | 1 |
| Kim, WS | 2 |
| Lee, YS | 2 |
| Cha, SH | 1 |
| Jeong, HW | 1 |
| Choe, SS | 1 |
| Lee, MR | 1 |
| Oh, GT | 1 |
| Park, HS | 1 |
| Lee, KU | 1 |
| Lane, MD | 1 |
| Kim, JB | 2 |
| Hu, Y | 2 |
| Davies, GE | 2 |
| Chen, C | 1 |
| Huang, C | 1 |
| Cheng, Z | 1 |
| Chen, AF | 1 |
| Sheng, L | 1 |
| Zhang, HK | 1 |
| Gu, M | 1 |
| Li, YY | 1 |
| Zhang, LN | 1 |
| Hu, LH | 1 |
| Li, JY | 1 |
| Li, G | 1 |
| Zhu, H | 1 |
| Huang, L | 1 |
| Ma, C | 1 |
| Qin, C | 1 |
| Shang, W | 1 |
| Zhao, J | 1 |
| Zhou, J | 1 |
| Zhou, S | 1 |
| Ikarashi, N | 1 |
| Tajima, M | 1 |
| Suzuki, K | 1 |
| Toda, T | 1 |
| Ito, K | 1 |
| Ochiai, W | 1 |
| Sugiyama, K | 1 |
| Han, J | 1 |
| Lin, H | 1 |
| Huang, W | 1 |
| Xie, W | 1 |
| Gu, D | 1 |
| Cui, K | 1 |
| Gomes, AP | 1 |
| Duarte, FV | 1 |
| Nunes, P | 1 |
| Hubbard, BP | 1 |
| Teodoro, JS | 1 |
| Varela, AT | 1 |
| Jones, JG | 1 |
| Sinclair, DA | 1 |
| Palmeira, CM | 1 |
| Rolo, AP | 1 |
| Hvistendahl, M | 1 |
| Ehli, EA | 1 |
| Kittelsrud, J | 1 |
| Ronan, PJ | 1 |
| Munger, K | 1 |
| Downey, T | 1 |
| Bohlen, K | 1 |
| Callahan, L | 1 |
| Munson, V | 1 |
| Jahnke, M | 1 |
| Marshall, LL | 1 |
| Nelson, K | 1 |
| Huizenga, P | 1 |
| Hansen, R | 1 |
| Soundy, TJ | 1 |
| Rahigude, AB | 1 |
| Kaulaskar, SV | 1 |
| Bhutada, PS | 1 |
| Kang, C | 1 |
| Li, M | 1 |
| Zhang, C | 1 |
| Kim, KH | 1 |
| Yoon, MJ | 1 |
| Cho, HJ | 1 |
| Shen, Y | 1 |
| Ye, JM | 1 |
| Lee, CH | 1 |
| Oh, WK | 1 |
| Kim, CT | 1 |
| Hohnen-Behrens, C | 1 |
| Gosby, A | 1 |
| Kraegen, EW | 1 |
| James, DE | 1 |
| Yin, J | 1 |
| Gao, Z | 1 |
| Liu, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Test the Efficacy of Novel Berberine Emulsification by TPGS or Quillaja Extract on the Absorption of Berberine Compared to Berberine Powder in Humans[NCT03438292] | 32 participants (Actual) | Interventional | 2018-09-25 | Completed | |||
| The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota[NCT04434365] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2019-06-21 | Active, not recruiting | ||
| The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial[NCT02806999] | Phase 4 | 200 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for berberine and Obesity
| Article | Year |
|---|---|
Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review.
Topics: Antineoplastic Agents; Berberine; Gastrointestinal Microbiome; Humans; Male; Obesity; Plants, Medici | 2022 |
The effect of Berberine on weight loss in order to prevent obesity: A systematic review.
Topics: Adipocytes; Berberine; Blood Glucose; Cholesterol; Gastrointestinal Microbiome; Gluconeogenesis; Hum | 2020 |
The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.
Topics: Berberine; Body Mass Index; Body Weight; Dietary Supplements; Humans; Hypoglycemic Agents; Obesity; | 2020 |
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.
Topics: Berberine; Dietary Supplements; Humans; Inflammation; Liver; Obesity; Randomized Controlled Trials a | 2020 |
Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease.
Topics: Berberine; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Liver; Non-alcoholic Fatty Liver D | 2021 |
Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
Topics: Berberine; Blood Glucose; Breast Neoplasms; Female; Humans; Incidence; Insulin Resistance; Metabolic | 2018 |
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
Topics: Antioxidants; Berberine; Curcumin; Dietary Supplements; Fatty Acids, Omega-3; Fatty Acids, Unsaturat | 2018 |
Modulating gut microbiota as an anti-diabetic mechanism of berberine.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Tract; Gene Expressio | 2011 |
1 trial available for berberine and Obesity
| Article | Year |
|---|---|
Lipid-lowering effect of berberine in human subjects and rats.
Topics: Adult; Animals; Berberine; Calcitriol; Cholesterol; Coptis; Drugs, Chinese Herbal; Female; Humans; H | 2012 |
58 other studies available for berberine and Obesity
| Article | Year |
|---|---|
Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice.
Topics: Animals; Berberine; Diet, High-Fat; Gastrointestinal Microbiome; Insulin Resistance; Mice; Mice, Inb | 2023 |
Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production.
Topics: Adenosine Triphosphate; Adipocytes, Brown; Adipose Tissue, Brown; Berberine; Chlorides; Diabetes Mel | 2023 |
Jatrorrhizine from Rhizoma Coptidis exerts an anti-obesity effect in db/db mice.
Topics: Alkaloids; Animals; Antineoplastic Agents; Berberine; Drugs, Chinese Herbal; Lipids; Mice; Mice, Obe | 2022 |
Berberine ameliorates mesenteric vascular dysfunction by modulating perivascular adipose tissue in diet-induced obese in rats.
Topics: Adipose Tissue; Animals; Berberine; Diet, High-Fat; Nitric Oxide; Obesity; Rats; Rats, Sprague-Dawle | 2022 |
A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ.
Topics: AMP-Activated Protein Kinases; Berberine; Humans; I-kappa B Kinase; Ibuprofen; Obesity; Protein Seri | 2022 |
A Composition of Phytonutrients for Glycemic and Weight Management.
Topics: Acrolein; Animals; Berberine; Blood Glucose; Curcumin; Diabetes Mellitus; Disease Models, Animal; Fa | 2022 |
Functional Complementation of Anti-Adipogenic Phytonutrients for Obesity Prevention and Management.
Topics: Adipocytes; Adipogenesis; Animals; Berberine; beta Catenin; Cholesterol; Curcumin; Cytokines; Fatty | 2022 |
Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut.
Topics: Animals; Berberine; Diet, High-Fat; Endocrine Cells; Glucagon-Like Peptide 1; Mice; Mice, Inbred C57 | 2022 |
Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Berberine; Body Weight; Growth Differentiation Fa | 2023 |
Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases.
Topics: Animals; Berberine; Cricetinae; Hyperlipidemias; Lipids; Metformin; Mice; Obesity | 2023 |
Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPARδ.
Topics: Animals; Berberine; Drugs, Chinese Herbal; Lipid Metabolism; Lipids; Mice; Obesity; PPAR delta; PPAR | 2023 |
Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3.
Topics: Adipocytes; Adiposity; Animals; Berberine; Cell Differentiation; Cell Proliferation; Diet, High-Fat; | 2019 |
Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2019 |
Development of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Obesity Agents; Berberine; Capsaicin; Catechin; Cell Surviva | 2020 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female | 2020 |
ATP reduces mitochondrial MECR protein in liver of diet-induced obese mice in mechanism of insulin resistance.
Topics: 3T3-L1 Cells; Adenosine Triphosphate; Animals; Berberine; Diet, High-Fat; Disease Models, Animal; Do | 2020 |
Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Differentiation; Chronic Disease; Cytokines; Dise | 2020 |
Regulation of MFN2 by berberine alleviates obesity exacerbated colitis.
Topics: Animals; Berberine; Colitis; Dextran Sulfate; Diet, High-Fat; Endoplasmic Reticulum Chaperone BiP; E | 2020 |
Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis.
Topics: Animals; Apoptosis; Berberine; Diet, High-Fat; Female; Gene Expression; Inflammation; Insulin Resist | 2021 |
Berberine for Appetite Suppressant and Prevention of Obesity.
Topics: Animals; Appetite Depressants; Berberine; Blood Glucose; Body Weight; Feeding Behavior; Leptin; Lipi | 2020 |
Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus.
Topics: Adiposity; Animals; Berberine; Body Weight; Diabetes, Gestational; Diet, High-Fat; Dietary Supplemen | 2021 |
Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinase Kinases; Animals; Berberine; Diet, High-Fat; Hom | 2021 |
Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota.
Topics: Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2021 |
Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3.
Topics: Adipose Tissue; Animals; Berberine; Diet, High-Fat; Inflammation; Insulin Resistance; Mice; MicroRNA | 2022 |
Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels.
Topics: Animals; Berberine; Dietary Fats; Endotoxemia; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Mal | 2017 |
Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway.
Topics: Animals; Berberine; Blood Glucose; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Drugs, | 2018 |
Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Berberine; Diet, H | 2018 |
Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice.
Topics: Animals; Berberine; Colon; Diet, High-Fat; Enterocytes; Fatty Acids; Glucagon-Like Peptide 1; Insuli | 2018 |
Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; | 2019 |
Berberine, a Traditional Chinese Medicine, Reduces Inflammation in Adipose Tissue, Polarizes M2 Macrophages, and Increases Energy Expenditure in Mice Fed a High-Fat Diet.
Topics: Adipose Tissue; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Berberine; China; Diet, High- | 2019 |
Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Topics: Acetylation; Acyl-CoA Dehydrogenase, Long-Chain; Animals; Berberine; Carnitine; Diet, High-Fat; Drug | 2019 |
Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Topics: Acetyl-CoA Carboxylase; Adenylate Kinase; Animals; Berberine; Carnitine O-Palmitoyltransferase; Diet | 2019 |
A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats.
Topics: 3T3 Cells; Adipogenesis; Adipose Tissue, White; Animals; Berberine; Diabetes Mellitus, Type 2; Femal | 2019 |
Berberine stimulates fibroblast growth factor 21 by modulating the molecular clock component brain and muscle Arnt-like 1 in brown adipose tissue.
Topics: Adipocytes, Brown; Animals; ARNTL Transcription Factors; Berberine; Diet, High-Fat; Dose-Response Re | 2019 |
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.
Topics: Adipocytes; Adipose Tissue, Brown; Adult; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agent | 2019 |
Berberine activates thermogenesis in white and brown adipose tissue.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Berberine; Drugs, Chinese Herbal; Energy Meta | 2014 |
Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters.
Topics: Animals; Berberine; Body Weight; Cholesterol; Cholesterol, LDL; Coptis; Diet, High-Fat; Disease Mode | 2015 |
Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats.
Topics: Animals; Anti-Obesity Agents; Bacteria; Base Sequence; Berberine; Diet, High-Fat; Fatty Acids, Volat | 2015 |
[Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance].
Topics: Animals; Berberine; Diet, High-Fat; I-kappa B Kinase; Insulin; Insulin Receptor Substrate Proteins; | 2015 |
Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Dietary F | 2016 |
Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model.
Topics: Animals; Berberine; Body Weight; Coptis; Diet, High-Fat; Hyperlipidemias; Hypolipidemic Agents; Insu | 2016 |
13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Alkaloids; AMP-Activated Protein Kinases; Animals; Anti-Obes | 2016 |
Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Topics: Animals; Bacteria; Berberine; Bile Acids and Salts; Body Weight; CD36 Antigens; Diet, High-Fat; Fece | 2017 |
Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.
Topics: Adenylate Kinase; Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Drug Evaluat | 2009 |
Berberine inhibits adipogenesis in high-fat diet-induced obesity mice.
Topics: 3T3-L1 Cells; Adipogenesis; Animals; Berberine; Blood Glucose; Cholesterol; Diet, Atherogenic; Dieta | 2010 |
Berberine inhibits PTP1B activity and mimics insulin action.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Diet; Female; Hyperglycemia; Hypoglycemic Agents; Insu | 2010 |
8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.
Topics: Animals; Berberine; Diabetes Mellitus; Electron Transport; Glucose; Humans; Hypoglycemic Agents; Mal | 2010 |
Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs.
Topics: Animals; Berberine; Cricetinae; Diabetes Mellitus, Type 2; Female; Gene Expression Profiling; Gene E | 2010 |
[Effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet].
Topics: Animals; Berberine; Dietary Fats; Disease Models, Animal; Glucose Tolerance Test; Humans; Inflammati | 2010 |
Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiposity; Animals; Berberine; Diabetes Mellitus, Type 2; Do | 2010 |
Inhibition of preadipocyte differentiation and lipid accumulation by Orengedokuto treatment of 3T3-L1 cultures.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Obesity Agents; Berberine; CCAAT-Enhancer-Binding Protein-al | 2012 |
Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Araceae; Bacteroidetes; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Feces; Gastr | 2011 |
Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Diet, High-Fat; Glucose; Hormones; Hyp | 2012 |
My microbiome and me.
Topics: Animals; Bacteria; Berberine; China; Diet; Drugs, Chinese Herbal; Gastrointestinal Tract; History, 2 | 2012 |
Possible therapeutic potential of berberine in diabetic osteopathy.
Topics: Berberine; Calcitonin; Diabetes Complications; Glucagon-Like Peptides; Glycation End Products, Advan | 2012 |
Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats.
Topics: Adiposity; Animals; Berberine; Diet, High-Fat; Fatty Acids, Volatile; Feces; Feeding Behavior; Gastr | 2012 |
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Cell Li | 2006 |
Berberine improves glucose metabolism through induction of glycolysis.
Topics: 3T3-L1 Cells; Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; AMP-Activated Protein Kin | 2008 |